enjoy

ride

Intercept Pharmaceuticals Inc

news

Every positive news is shorted to oblivion.

Getting the feeling they will have bad news soon.

No possible good news can come out in months and months

management

Definitely bad management, and a product that almost no one seem to believe in anymore.

Management just needs to get their asses in gear and get the sNDA refiled ASAP.

$ICPT insanity how much incompetence this management has!!!!

Now management’s sluggish pace ensures the downward spiral will continue,

$ICPT unbelievable how much time and money this management has WASTED

And this is a highly risky stock because mgt is not strong and does not communicate.

drug

RETA just did as there wasn&#39;t any treatment for their indication.

I don’t buy that because this was a Trial Drug !!

It’s a shame that no currently approved medications exist for the treatment of NASH

business-result

but it looks like too risky with mixed trials results.

Huge disappointment after nearly a year delay to get bad results. Sigh

but then again they have emphasized they dont need Reverse to submit Regenerate results and no additional safety is what they observed.

company

$ICPT We’re trading like a standalone PBC company, which is ridiculous.

$ICPT Well, looks like this company cannot do good for WS, we are again price as if all failed two month before AdCom.

No one has any confidence in this company, or this is pure manipulation by some greedy parties.

$ICPT this is dumb, the company mentioned many times there will be an adcom

So tired of this company and the way it acts.

I am at a loss, this is surely manipulation, someone wants this company to fail.

$ICPT Clearly the market has no faith in this company.

Let me close by saying incompetence of the company was by a few not a whole

These idiots will announce a delay in resubmitting on the last business day of the year just to guarantee they destroy this company.

approval

I predict the Adcom Board will give OCA thumbs up and then a swift approval thereafter.

So much potential upside if/when approved for NASH.

We are unanimously gonna get the thumbsup at Adcom in light of extensive efficacy and safety data and OCA is gonna be approved before the set Pdufa date unexpectedly.

$ICPT getting an Adcomm; this is positive, there is no doubt in my mind, that Adcomm panel will understand Risk/Benefit warrants approval.

What approval will do is finally give patients some hope and will put ICPT on the path to long term profitability.

Any weakness today will be recovered quickly by close , their safety profile for OCA is good and should go a long way helping with approval for NASH , my take . GLTA

This will rise and once approved, we&#39;ll get our BO is my guess.

MDGL once it is approved will dominate this market

quot

,&quot; We are really excited about the fixes combination of OCA plus bezafibrate.

So we feel comfortable that the work we&#39;re -- the ground work that we led with PBC will translate very efficiently into a NASH, potential NASH launch.&quot; Linda Richardson

$ICPT &quot;NDA is supported by robust NASH clinical development program, including two positive interim analyses from the Phase 3 REGENERATE study demonstrating OCA&#39;s improvement in liver fibrosis without worsening of NASH&quot;

This efficacy, together with extended exposure in the largest safety database in NASH, supports a positive benefit:risk for OCA in patients with fibrosis due to NASH,&quot;

This is a 16.43 percent increase over sales of $66.64 million the same period last year.&quot;

Importantly, given the recent strategic transactions that have strengthened our capital structure, we are well-positioned financially to manage this critical time while building for the future.&quot;

&quot;This quarter&#39;s performance reinforces the underlying strength and value of our PBC business, and there is significant opportunity to grow this franchise given the number of patients who remain eligible for second-line therapy.

application

Adcom is only a positive thing what the company wanted and they have emphasized that numerous times.

This should start the ascent soon in anticipation of FDA outcome which is leaning positive to me , just my take GLTA

$ICPT I am glad the application was accepted, otherwise we would have been at $5, if that

It is obvious that ICPT took care of the issues of concerns from the first application.

In these analyses, OCA 25 mg consistently demonstrated double the response rate of placebo in reduction in liver fibrosis stage without worsening of any of the three histologic components of NASH, an endpoint consistent with FDA&#39;s draft guidance.

“We believe OCA has the potential to become an important therapy given its strong and direct antifibrotic effect, and we look forward to continuing our work with FDA over the coming months as they review our NDA.” $ICPT

Nabors Industries Ltd

Himax Technologies, Inc.

$HIMX Seriously talking, it’s a shame that a company making $1.36 EPS with a 2.8P/E trades at $7.

That&#39;s a huge problem for this company! Lol!!!!.

$HIMX 

CC: HX_IR@himax.com.tw

Hi Himax team
I find it completely unacceptable for a listed company to present the dismantling of one of its most strategic assets without mentioning the transaction values involved.

They should just be a private company managed by 2 brothers.

market

$HIMX the markets have become totally unhinged.

$HIMX Broad mkt is bleeding in PM, not looking good today.

Not necessarily good news as they never admit defeat,  could be a feint for market sympathy or some other CCP trick…

Quite obviously nothing works 100% of the time in the stock market especially the way this stock is manipulated

This is the saddest story in equity markets.

suck

$HIMX really fucked up back test of the 200dma. .

$HIMX nowhere near the 200dma &amp; still getting fucked around.

price

$HIMX more annoying than the drop in price last few days, is the miniscule volume.

but today&#39;s price was very disappointing compared to most all other semi stocks.

$HIMX Some seriously dumb price action here.

but so far this price action is disappointing.

$HIMX Very frustrating how they can drop price so much with so little volume.

dividend

Preliminary, Unaudited Fourth Quarter 2022 Financial Results 
- Revenues were $262.3 million, an increase of 22.8% from the third quarter of 2022, substantially  
outperforming the guidance range of around a 4% - 8% sequential increase.

Preliminary, Unaudited Fourth Quarter 2022 Financial Results -  
Revenues were $262.3 million, an increase of 22.8% from the third quarter of 2022, substantially outperforming the guidance range of around a 4% - 8% sequential increase.

$HIMX  Great quarter for Himax (HIMX) with bright outlook for Q4, so the worst is behind us!

$HIMX  Solid quarter w/ good guidance for Q4.

$HIMX Considering the world economies and such, I am mostly pleased with the 3Q results and 4Q guidance.

$HIMX P/B now 1, profitable company with high dividends .

For comparison, HIMX is strongly profitable, pays a rich dividend every year and its current EV is about 1 times this year&#39;s est. Revenue!!!

Another fat rich dividend payment is on the horizon!

$HIMX makes money, pays a yearly dividend and IP is strong

High Dividends can easily offset inflation.

However, Good to see the &quot;all knowing&quot; face coming back with a big bang comment.

Top Stocks matching your search for "enjoy ride"

Click Learn More to know about Stock Advisor's top picks. We've 3x'd the S&P 500 over the last 20 years.

ICPT

Intercept Pharmaceuticals Inc

-34.51%

$20.75 - $13.59

Dec, 25, 2022

NBR

Nabors Industries Ltd

-40.45%

$187.99 - $111.95

Nov, 6, 2022

HIMX

Himax Technologies, Inc.

-7.85%

$8.41 - $7.75

Nov, 10, 2022

ICPT

Intercept Pharmaceuticals Inc

-34.51%

$20.75 - $13.59

Dec, 25, 2022

NBR

Nabors Industries Ltd

-40.45%

$187.99 - $111.95

HIMX

Himax Technologies, Inc.

-7.85%

$8.41 - $7.75

Nov, 10, 2022